Keywords: biogen, idec, sees, 4th-qtr, sales, rise, world
Biogen Idec sees 8% 4th-qtr 2005 sales rise
Article | 27 February 2006
The world's third-largest biotechnology firm, Biogen Idec, says that fourth-quarter 2005 revenues reached $633.0 million, up 8% year-on-year, marginally beating Wall Street expectations.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
